In the last decades the molecular basis of monogenic diseases has been largely unraveled, although their treatment has often remained unsatisfactory. Autosomal recessive osteopetrosis (ARO) belongs to the small group of genetic diseases that are usually treated with hematopoietic stem cell transplantation (HSCT). However, this approach is not effective in the recently identified form carrying mutations in the receptor activator of NF-kB ligand (RANKL) gene. In this subset, therapy replacement approach based on RANKL delivery has a strong rationale. Here we demonstrate that the systematic administration of RANKL for 1 month to Rankl-/- mice, which closely resemble the human disease, significantly improves the bone phenotype and has beneficial effects on bone marrow, spleen and thymus; major adverse effects arise only when mice are clearly overtreated. Overall, we provide evidence that the pharmacological administration of RANKL represents the appropriate treatment option for RANKL-deficient ARO patients, to be validated in a pilot clinical trial.

Osteopetrosis rescue upon RANKL administration to Rankl(-/-) mice : a new therapy for human RANKL-dependent ARO / N. Lo Iacono, H.C. Blair, P.L. Poliani, V. Marrella, F. Ficara, B. Cassani, F. Facchetti, E. Fontana, M.M. Guerrini, E. Traggiai, F. Schena, M. Paulis, S. Mantero, A. Inforzato, S. Valaperta, A. Pangrazio, L. Crisafulli, V. Maina, P. Kostenuik, P. Vezzoni, A. Villa, C. Sobacchi. - In: JOURNAL OF BONE AND MINERAL RESEARCH. - ISSN 0884-0431. - 27:12(2012 Dec), pp. 2501-2510. [10.1002/jbmr.1712]

Osteopetrosis rescue upon RANKL administration to Rankl(-/-) mice : a new therapy for human RANKL-dependent ARO

N. Lo Iacono
Primo
;
B. Cassani;M.M. Guerrini;A. Inforzato;
2012-12

Abstract

In the last decades the molecular basis of monogenic diseases has been largely unraveled, although their treatment has often remained unsatisfactory. Autosomal recessive osteopetrosis (ARO) belongs to the small group of genetic diseases that are usually treated with hematopoietic stem cell transplantation (HSCT). However, this approach is not effective in the recently identified form carrying mutations in the receptor activator of NF-kB ligand (RANKL) gene. In this subset, therapy replacement approach based on RANKL delivery has a strong rationale. Here we demonstrate that the systematic administration of RANKL for 1 month to Rankl-/- mice, which closely resemble the human disease, significantly improves the bone phenotype and has beneficial effects on bone marrow, spleen and thymus; major adverse effects arise only when mice are clearly overtreated. Overall, we provide evidence that the pharmacological administration of RANKL represents the appropriate treatment option for RANKL-deficient ARO patients, to be validated in a pilot clinical trial.
BONE; OSTEOPETROSIS; RANKL; THERAPY; HEMATOLYMPHOID COMPARTMENT
Settore BIO/17 - Istologia
26-lug-2012
Article (author)
File in questo prodotto:
File Dimensione Formato  
1712_ftp.pdf

accesso riservato

Descrizione: Articolo principale
Tipologia: Publisher's version/PDF
Dimensione 1.84 MB
Formato Adobe PDF
1.84 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/263528
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 33
social impact